Clinical Trials · NCT01069094
A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Repros Therapeutics Inc.
- Enrollment
- 29
- Start date
- Jul 2004
- Locations
- 1 site, Poland
- Primary endpoint
- Assess the safety of Progenta when administered in pre-menopausal women with symptomatic leiomyomata.